Top Tweets for #Checkmate816
Neoadjuvant nivolumab+chemo is changing the game in early-stage #NSCLC:
📊 #CheckMate816 & #NADIM show⬆️pCR,⬇️recurrence,⬆️survival
🧬ctDNA clearance may signal real cure
🎯Immunotherapy isn’t just life-prolonging—it’s aiming for remission
#LungCancer #Oncology #NEJM #MedTwitter
🚨Update survival data published in @NEJM today. Final OS results from #CheckMate816: Neoadjuvant nivolumab + chemo significantly improves survival vs chemo alone in resectable NSCLC. A landmark step confirming long-term benefit. @OncoAlert @oncodaily
Game-changer in resectable NSCLC:
Neoadjuvant nivolumab + chemo → 5-yr OS 65% vs 55%.
Patients achieving pCR: OS ≈ 95% 🔥
The role of preoperative immunotherapy is becoming undeniable👀
#lungcancer #oncology @OncoAlert
#ASCO25: Final results from #CheckMate816 confirm OS benefit—nivolumab + chemo cuts risk of death by 28% in resectable #NSCLC. 5-year OS: 65.4% vs 55.0%. A paradigm shift is now standard. https://t.co/D0YPhPPFBz @HendriksLizza @FordePatrick @NEJM
⭕Confirmado: la inmunoterapia antes de la cirugía mejora la supervivencia en cáncer de pulmón.
🗣️“El cambio de paradigma es definitivo”, afirma @MARIANOPROVENCI sobre #CheckMate816.
👉 Se duplica la esperanza de vida en estadios intermedios.
https://t.co/N6Dosyj9vI
#GECP #ASCO25 #Oncologia
Nivolumab +Chemotherapy given before surgery shows promising results improving OOS at 5 years vs chemo alone in a subset of non small cell lung cancer patients
the #CheckMate816 study
https://t.co/xdKBocDtmE
#ASCO25: Final results from #CheckMate816 confirm OS benefit—nivolumab + chemo cuts risk of death by 28% in resectable #NSCLC. 5-year OS: 65.4% vs 55.0%. A paradigm shift is now standard. https://t.co/D0YPhPPFBz @HendriksLizza @FordePatrick @NEJM
@Larvol Quick Takes: At @ASCO 2025, Dr. Nicolas Girard (@nicogirardcurie) talks to Bruno Larvol (@brunolarvol) about CheckMate 816.
Discover more about CheckMate 816: https://t.co/Fu2WK8F3PS
#LARVOL #ASCO25 #CheckMate816 #CancerResearch #Oncology #ClinicalTrials #CancerData #CancerCare #LungCancer #ASCO2025
My takeaways from #CheckMate816 update in @NEJM:
1⃣ pCR confirmed as surrogate for OS
2⃣ Supports not offering adjuvant IO if pCR achieved
3⃣ ctDNA clearance still not ready for clinical decision-making
https://t.co/RedoUeeaw3
#LCSM @OncoAlert
3. #Checkmate816: Chemo + Nivo update (already approved) in neoadj resectable NSCLC.
- 5yr OS 65.4% vs 55.0 (HR: 0.72). Majority of the benefit driven by PDL1 ≥1% (HR: 0.51)
- mOS NR vs. 73.7mos
- ctDNA clearance prior to ✂️ associated w/ OS.
4/8
🫁 #LungCancer Oral Abstract Session #ASCO25
CheckMate 816: Neoadjuvant Chemo + Nivolumab vs. Neoadjuvant Chemo alone
🔹HR 0.72 (0.523-0.998), mOS: NR vs. 73.73 mo for chemo
🔹5-yr EFS 49% vs. 34%
🔹5-yr OS of pts with pCR: 95% (HR 0.11)
🔹Pre-surgical ctDNA clearance assoc w/ OS improvement
#LCSM @FordePatrick
🚨 Final 5y OS results from #CheckMate816 at #ASCO25:
presented by @FordePatrick
🧬 #Nivo #preop+ chemo in resectable NSCLC:
✅ OS benefit vs chemo (HR 0.72; p=0.0479)
✅ 5y OS: 65% vs 55%
✅ Benefit consistent across stages, PD-L1, histologies
🧫 ctDNA clearance = improved OS
🔥🚨@OncoAlert Hot Off The Press.
Just presented @ASCO #ASCO25 by the amazing @FordePatrick
#OverallSurvival Results of #Checkmate816 phase 3 trial of:
#Neoadjuvant #Nivolumab + Chemo vs Chemo in stage IB-IIIA Non-Small-Cell #LungCancer
👇🏻
🔥🚨@OncoAlert Hot Off The Press
Just published @NEJM in conjunction with presentation @ASCO #ASCO25
#OverallSurvival Results of #Checkmate816 phase 3 trial of:
#Neoadjuvant #Nivolumab + Chemo vs Chemo in stage IB-IIIA Non-Small-Cell #LungCancer
✅#OS: HR: 0.72 (5-year: 65.4% vs 55%)
mOS:
-Not reached for Nivo + Chemo
-73.7 months for Chemo
👇🏻
https://t.co/DnotCC2VQA
🔥🚨@OncoAlert Hot Off The Press
Just published @NEJM in conjunction with presentation @ASCO #ASCO25
#OverallSurvival Results of #Checkmate816 phase 3 trial of:
#Neoadjuvant #Nivolumab + Chemo vs Chemo in stage IB-IIIA Non-Small-Cell #LungCancer
✅#OS: HR: 0.72 (5-year: 65.4% vs 55%)
mOS:
-Not reached for Nivo + Chemo
-73.7 months for Chemo
👇🏻
https://t.co/DnotCC2VQA
Landmark OS data from #CheckMate816 just dropped in @NEJM!
🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers:
✅ 5-yr OS: 65.4% vs 55.0%
✅ HR: 0.72 (p=0.048)
✅ Lung cancer–specific survival HR: 0.65
✅ OS with pCR: 95.3%
✅ ctDNA clearers: 75%+ OS
📌 No lung cancer deaths in pCR patients
#LungCancer #Immunotherapy #ASCO25 #Oncology @FordePatrick @asco @OncoAlert
🔥🚨@OncoAlert Hot Off the Press
BIG NEWS Press Release by @bmsnews
#CheckMate816 phase 3 trial of #Nivolumab + Chemo as #Neoadjuvant (only) Tx for resectable Non-Small-Cell #LungCancer shows statistically significant improvement⬆️in #OverallSurvival
👇🏼
https://t.co/l9x1UkgUKf
📌Consolidating a new standard of care in early stage lung cancer
🏫started at @gecp_org
‼️Bravo @MARIANOPROVENCI and colleagues
#ASCO24 #CheckMate816
Patient-centered summary of the #CheckMate816 neoadjuvant chemo-immunotherapy clinical trial. This is a new treatment for patients with stage 1-3 non-small-cell lung cancer that can be removed by surgery. The summary may be useful for clinicians & patients. #lcsm @LUNGevity
#ESMO23 - #BMS announced three-year #CheckMate816 trail results demonstrating the advantage of #Opdivo as neoadjuvant therapy in #NSCLC patients
https://t.co/wpy6ItUDPa
#pharma #pharmaceutical #Science #news #media #medicine #Europe #patientcare #healthcare #ESMO2023 #Health
🔴@gecp_org aplaude la aprobación @EMA_News de Nivolumab + quimioterapia antes de cirugía en CPNM
👉Un gran paso para los pacientes pese a que de momento está restringido a PDL1+
🚩Basado en datos de #CheckMate816 cuyo germen es estudio #NADIM GECP
➕https://t.co/xuh8CiAGN8 👇👇
#ELCC23 | #Nivolumab + platinum-doublet chemotherapy for adult patients with resectable #NSCLC in the neoadjuvant setting: 31.6 months EFS and 24% pCR rate in the combo arm VS 20.8 months and 2.2% for chemotherapy alone.
#CheckMate816
https://t.co/AeH43cCdHl
#ScienceLink #Nivolumab #CheckMate816
Nivolumab + QT neoadyuvante demostraron mejoras en la SLE, en el tiempo hasta la metástasis a distancia y en la SG.
https://t.co/4ymhOZtOvz
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers